Cnpy2 knockout protects multiple cell types against ER stress in vitro and in vivo CNPY2 is an ER protein belonging to the CNPY family that also contains CNPY1, CNPY3 and CNPY4. These proteins share a conserved six-cysteine pattern, characteristic of saposin-like proteins, and an ER retention signal at the C terminus 17 . The known functions of CNPY2 are limited, although CNPY2 was reported to positively promote neurite outgrowth by stabilizing the myosin regulatory light chain 18 . It has also been reported to promote angiogenesis and prevent hypertrophic cardiomyopathy 19, 20 . However, the ER function of CNPY2 hitherto remains unknown. We took a genetic approach to address this question by generating a Cnpy2-knockout (KO, Cnpy2 −/− ) mouse model (Supplementary Fig. 1a ). The deletion of CNPY2 in a variety of organs was confirmed by immunoblotting ( Supplementary Fig. 1b) . At baseline, Cnpy2 KO mice are consistently slightly smaller than their wild-type (WT) or Cnpy2 heterozygous (Het) counterparts; however, they do not exhibit developmental defects and are fertile. The KO mice survive beyond 16 months old under specific-pathogen-free conditions and display a normal liver histology (Supplementary Fig. 1c ) with preserved baseline liver function (Supplementary Fig. 1d ).
a r t i c l e s
The UPR is activated in response to the accumulation of misfolded or unfolded proteins [1] [2] [3] [4] , which play increasingly recognized roles in protein quality control and cell-fate determinations 5 . UPR mediates cell adaptation and survival in response to protein overload in the secretory pathway by reducing the amount of proteins translocated into the ER lumen, increasing retrotranslocation of luminal proteins to the cytosol, degrading ER-targeted proteins and augmenting the protein-folding capacity of the ER. However, if the attempt to recover from ER stress fails, the UPR will trigger an irreversible cell-death program to eliminate the stressed cells 6 . The basic UPR pathways in mammalian cells consist of three main signaling branches initiated by three primary ER-membrane-localized UPR sensors: inositol-requiring enzyme 1 (IRE1), PERK and activating transcription factor 6 (ATF6). Under normal conditions, the luminal portions of these molecular sensors are bound to the abundant ER luminal chaperone grp78 to prevent activation of their downstream events. However, when misfolded or unfolded proteins accumulate in the ER lumen, grp78 dissociates from the stress sensors to chaperone the misfolded or unfolded proteins, leading to activation of the sensors on the ER membrane and initiation of the UPR 7, 8 . Notably, unfolded proteins or lipids may also bind directly to UPR sensors and favor their homodimerization and downstream signaling [9] [10] [11] . A key unresolved question is whether grp78 dissociation from these ER sensors or binding of misfolded proteins to the sensors is independently sufficient to activate the UPR, or whether additional upstream molecular interactions play essential roles 12 . A recent study showed that the ER luminal enzyme PDIA6 controls IRE1 activity 13 . PDIA6 itself is positively regulated by thioredoxin-interacting protein 14 and negatively regulated by microRNA-322 (ref. 15 ) and thereby plays important roles in tuning the UPR. The ER protein thrombospondin binds to ATF6α and promotes its nuclear translocation 16 . This evidence suggests that other ER molecules besides grp78 may be required in order to trigger the UPR sensors. In the current work, we show for the first time that the ER protein CNPY2 regulates the PERK pathway.
To gain insight into the role of CNPY2 in the UPR, we treated WT and KO mice using a well-defined pharmacological UPR inducer, tunicamycin (Tu), which causes protein misfolding in the ER by blocking N-linked glycosylation and triggers significant hepatic steatosis, a pathophysiological hallmark of ER stress 21 . Whereas the body weight of Het control mice decreased (by ~5%) 24 h post Tu treatment, KO mice did not exhibit significant weight loss (Student's t test, Supplementary Fig. 1e ). As expected, levels of a key downstream PERK molecule, CHOP, increased significantly in the livers and kidneys of Tu-treated WT and Het mice. In contrast, CHOP induction was abrogated in the respective organs of the KO mice ( Fig. 1a) . Consistent with the known connection between the UPR and hepatic steatosis 21 , significant liver damage and hepatosteatosis were observed histologically by hematoxylin and eosin (H&E) and oil red O staining, respectively, in WT and Het mice, but not in KO mice (Fig. 1b) . Further, the serum levels of alanine aminotransferase (ALT), a biomarker for liver injury, increased significantly post Tu treatment in Het mice compared to KO mice ( Fig. 1c) . Of note, WT and Het mice exhibited similar levels of total bilirubin and albumin (data not shown). Notably, RT-qPCR analysis showed no significant differences in induction of the spliced form of the Xbp1 transcript (Xbp1s) or its downstream genes Edem1 and Erdj4, regardless of Cnpy2 genotype ( Supplementary Fig. 2a,b) . To further confirm the protective effect of Cnpy2 KO against ER stress, primary hepatocytes were isolated from WT, Het and KO mice and then treated with thapsigargin (TG, another UPR inducer that acts via inhibition of sarcoplasmic reticulum and endoplasmic reticulum Ca 2+ ATPase), Tu, or DMSO (control). Cnpy2 deletion protected isolated hepatocytes against TG-or Tu-induced cell death (Fig. 1d) . This protection was further evidenced by the concomitant diminution upon TG or Tu exposure in the levels of ER stress and UPR-associated proteins, including CHOP, phospho-eif2α and the apoptosis regulator BAX, in Cnpy2 KO hepatocytes compared to WT and Het hepatocytes ( Fig. 1e) . Interestingly, there was no difference in the induction of grp78 by Tu between WT, Het and KO cells ( Fig. 1a,e ), and consistent with our in vivo data, Xbp1s mRNA was similarly induced by Tu in WT, Het and KO hepatocytes in vitro (Supplementary Fig. 2c ). Together, these data suggest that CNPY2 has a role in the UPR and that its loss protects hepatocytes against ER stress.
Cnpy2 deletion protects mice from hepatic steatosis
The UPR has been closely linked to nonalcoholic fatty liver disease (NAFLD) [22] [23] [24] [25] . Thus, we assessed the role of CNPY2 in this pathophysiological setting. We used a high fat diet (HFD)-induced ER stress model a r t i c l e s a r t i c l e s and specifically investigated the effect of CNPY2 loss on ER stress and NAFLD. To this end, male Cnpy2 Het and KO mice were fed with a HFD for 10 weeks. Although all mice showed body-weight increase after 10 weeks, KO mice gained significantly less body weight compared to the Het littermate controls ( Fig. 2a) . Grossly, Het livers appeared paler and more buoyant than the KO livers, indicating potential differences in liver fat content between HFD-fed Het and KO mice ( Fig. 2b) . Indeed, H&E and oil red O staining demonstrated a striking distinction between Het and KO livers, with the former heavily loaded with lipid droplets in hepatocytes ( Fig. 2c) . As expected, HFD induced a remarkable increase of the UPR markers in the livers of Cnpy2-sufficient mice (Het), which were dramatically reduced in the KO livers ( Fig. 2d) . Correspondingly, increased levels of ALT and triglycerides after 10 weeks of HFD feeding were observed in the Het but not in the KO mice ( Fig. 2e) . These data strongly suggest that UPR contributes to NAFLD, and the loss of CNPY2 considerably attenuates the disease progression.
CNPY2 interacts with PERK
ER stress is known to trigger grp78 dissociation from the UPR sensors 7, 8 . Because our data suggest involvement of CNPY2 in the UPR, we next sought to determine whether CNPY2 directly binds to the UPR sensor PERK to initiate the PERK-CHOP pathway. We addressed this possibility using both cell-based and cell-free systems. We treated HEK293 cells that expressed Myc-tagged grp78 and FLAG-tagged CNPY2 with Tu and then performed sequential immunoprecipitation (IP) experiments. Our data indicate that under nonstress conditions, CNPY2 interacts with grp78; however, this interaction is reduced upon ER stress induction ( Fig. 3a) . A similar finding was observed using the macrophage-like leukemic cell line RAW264.7 ( Supplementary Fig. 3a,b) .
To probe the interaction between CNPY2 and PERK, FLAG-tagged CNPY2 and Myc-tagged PERK were transiently cotransfected into HEK293 cells. We found that CNPY2 coimmunoprecipitated with PERK ( Fig. 3b ). Furthermore, we confirmed the direct binding between purified CNPY2 and the PERK luminal domain (PERK-LD) by means of a pulldown experiment ( Fig. 3c ) and isothermal titration calorimetry (ITC) ( Fig. 3d) . ITC is a quantitative technique that can determine the binding affinity (K d ), enthalpy changes (∆H) and stoichiometry of protein-protein interactions. Data from the ITC indicated that PERK-LD directly binds to CNPY2 with one active binding site (n = 1.162 ± 0.007) and a moderate binding affinity (K d = 13.15 ± 0.3 µM) ( Fig. 3d) . The presence of six conserved cysteine residues in CNPY2 suggests that intramolecular or intermolecular disulfide bond formation are involved in CNPY2 function. To test this possibility, we generated a CNPY2 mutant termed 6C-A in which all of the cysteines were mutated to alanines (C28A C31A C86A C137A C164A C171A) and then performed ITC. Intriguingly, we found that the 6C-A mutation completely abrogated CNPY2 binding to PERK-LD ( Supplementary Fig. 4 ), suggesting that the cysteine residues are important for the CNPY2-PERK interaction. Because grp78 has been well documented to bind to PERK and the kinase activity of PERK can be regulated by other molecules, including TBL2 and p58IPK (refs. 26, 27) , we hypothesized that CNPY2 competes for PERK binding. Therefore, we sought to determine whether CNPY2 competes with grp78 for binding to PERK. Indeed, in a cell-free system, CNPY2 dissociated grp78 from the complex with PERK-LD in a dose-dependent manner (Fig. 3e ). This result also suggests that under this experimental condition, CNPY2, PERK and grp78 do not form a trimeric complex. To further examine the functional consequence of the interaction between CNPY2 and PERK, we performed an in vitro kinase assay for PERK with or without CNPY2. We found that immunoprecipitated Myc-PERK phosphorylated its bona fide substrate glutathione S-transferase (GST)-tagged eif2α (GST-eif2α) but not the GST-eif2α S51A mutant, which has a mutated PERK phosphorylation site. Addition of CNPY2 led to a reproducible two-fold increase in the phosphorylation level of GST-eif2α by Myc-PERK ( Fig. 3f ).
Structure-function study of CNPY2 in activating PERK pathway
To further address the potential roles of disulfide bond formation in CNPY2 function, we mutated the three cysteine residues in the N-terminal half of CNPY2 to alanines (C28A C31A C86A). Surprisingly, we found that this triple cysteine mutant (3C-A) interacted with equal efficiency, if not higher efficiency, with PERK-LD (3C-A:PERK stoichiometry = 1.0366 ± 0.014; K d = 7.5 ± 0.1 µM) compared to the WT CNPY2 ( Fig. 4a,b) . Additionally, the 3C-A mutant was more active and displayed an increased propensity to promote PERKmediated phosphorylation of GST-eif2α ( Fig. 4c ). Next, we performed rescue experiments using Cnpy2 KO mouse embryonic fibroblasts (MEFs) to further understand the structure-function relationship of CNPY2. We stably expressed WT CNPY2 as well as the 3C-A and 6C-A mutants in the MEFs. In line with our earlier data, and based on the a r t i c l e s differential migration pattern on reducing and nonreducing gels, we observed only the WT and 3C-A mutant, and not the 6C-A mutant, formed disulfide-bond-dependent complexes (Fig. 4d) . The 3C-A mutant is not stable and has a shorter half-life compared to WT and the 6C-A mutant (Supplementary Fig. 5a ). Intriguingly, we found that the PERK-CHOP signal was completely restored in response to Tu by the WT and 3C-A mutant but not the 6C-A CNPY2 mutant ( Fig. 4e) . Notably, 3C-A expression level decreased after Tu treatment despite induction of CHOP, suggesting that CNPY2 initiates but is not required for sustaining the UPR. Importantly, overexpression of 3C-A mutant does not activate the UPR in WT MEFs in the absence of ER stress ( Supplementary Fig. 5b ), suggesting that 3C-A per se does not act as a misfolded protein to trigger UPR. Overall, our data demonstrate the importance of the CNPY2 disulfide-bond-formation property in activating the PERK-CHOP pathway.
CHOP regulates CNPY2 transcription
The transcriptional mechanism of CNPY2 regulation is unknown, but given the strong induction of CHOP by ER stress (Fig. 1) , we next determined whether CHOP could directly transactivate Cnpy2. CHOP is a transcription factor that transactivates multiple UPR target genes such as Il23a and Atp2a1 (refs. 28, 29) . Comparative promoter analysis of the human Cnpy2 gene and its orthologs revealed that these genes share a CHOP consensus-recognition motif ( Fig. 5a ). Using an oligonucleotide pulldown assay, we found that the Cnpy2 promoter binds to CHOP upon Tu treatment. This interaction was competitively attenuated by the nonbiotinylated oligonucleotide corresponding to the CHOP-binding motif in the Cnpy2 promoter ( Fig. 5b) . The occupancy of the Cnpy2 promoter by CHOP was also confirmed by a chromatin immunoprecipitation (ChIP) assay ( Fig. 5c) . Additionally, overexpression of CHOP increased the promoter activity of Cnpy2 in HEK293 cells ( Fig. 5d ) and upregulated the expression of CNPY2 (Fig. 5e) . These results suggest that CHOP regulates UPR in part by positively modulating the expression of CNPY2.
DISCUSSION
The lumen of the ER provides an environment that is specialized for the production of membrane and secretory proteins. The UPR pathway functions as a barometer of protein stress, and it provides an intricate monitoring system in response to alterations in ER homeostasis. The UPR pathways are tuned constantly during normal and stress conditions. Nevertheless, how the UPR sensors are triggered molecularly is not entirely clear 12, 30 . In one model, grp78 binds to and sequesters all three UPR sensors (PERK, IRE1 and ATF6) in an inactive state under normal conditions. Upon ER stress, accumulated unfolded proteins trigger dissociation of grp78 from the UPR sensors and activate the UPR by facilitating PERK dimerization, IRE1 Supplementary Table 1 . a r t i c l e s autophosphorylation and ATF6 translocation to the Golgi apparatus.
Another model implies the direct interaction between unfolded or misfolded proteins and the UPR sensors to trigger the UPR 10 . A third model relates to the requirement of both grp78 dissociation from and misfolded protein binding to UPR sensors. One key question remaining is whether these three models uncover all of the mechanisms of UPR activation or whether some other, as-yet-unidentified molecules are required in the process of UPR activation. In the present study, we provide the first evidence that CNPY2 acts as a major trigger for the PERK-CHOP pathway. In the absence of CNPY2, the PERK pathway was impaired in both in vivo (liver and kidney) and in vitro (primary hepatocytes and MEFs). Molecularly, we found that during transition from nonstress status to stress conditions, CNPY2 switches its binding partner from grp78 to PERK, which coincides with PERK activation. Intriguingly, we found no evidence for grp78 and CNPY2 copresenting in a complex with the UPR sensors, suggesting that perhaps the binding regions of the UPR sensors are only assessable to CNPY2 after grp78 dissociation. The importance of CNPY2 in UPR was further demonstrated using our in vitro reconstitution system, in which we found CNPY2 to directly promote the enzymatic activity of PERK kinase. Finally, we found that CNPY2 itself is also regulated by the UPR via direct transcriptional activation by CHOP. The UPR has been closely linked to NAFLD, although it remains to be resolved whether NAFLD is the result of UPR dysfunction or a cause. Some studies support the notion that ER dysfunction and UPR activation precedes hepatic steatosis, consequently causing the disease 22,23,31-33 . Conversely, there is evidence suggesting that ER dysfunction and UPR activation is the result of lipid accumulation in hepatocytes 34 . Most of the studies examining this question are based on perturbation of one branch of UPR pathways, which often give rise to conflicting results. For example, deletion of Xbp1 makes hepatocytes more resistant to develop HFD-induced steatosis 35 , whereas deleting Ire1 in hepatocytes worsens NAFLD 21 . Silencing Atf6 in zebrafish results in a reduction of steatosis incidence caused by prolonged ER stress but increases it in response to acute ER stress 22 . Studies with Atf6-null mice show similar results 23, 36 . The fact that CNPY2 is required to elicit the PERK pathway presented a unique opportunity for us to re-examine the roles of this pathway in NAFLD. We found that deletion of Cnpy2 blocked the PERK-CHOP pathway, and this had strong protective effects against NAFLD induced either acutely with tunicamycin or chronically by HFD. Thus, our work strongly suggests that the UPR contributes causally to NAFLD. Our work is consistent with the study that found that silencing grp78, a main regulator of all three UPR pathways, leads to the alleviation of NAFLD 24 . In addition, Atf4-null mice phenocopy Cnpy2 KO mice in that they are both protected against HFD-induced hepatosteatosis 25 Most importantly, our study has uncovered a fundamental role of CNPY2 in initiating PERK-CHOP-mediated UPR (Fig. 6) . In the nonstress conditions, both PERK and CNPY2 are sequestered by grp78. During the transition from nonstress to stress conditions, grp78 disassociates from PERK and CNPY2, thereby allowing free CNPY2 to interact with PERK. Consequently, the enzymatic activity of PERK kinase increases, leading to a cascade of events including induction of CHOP. This concept is analogous to the IRE1-XBP1s pathway in that multiple interacting molecules come together during ER stress to form the UPRosome signaling platform to initiate the UPR 37 . Finally, CNPY2 is itself upregulated by UPR via direct transcriptional activation by CHOP, further enhancing the activity of the PERK pathway to cope with ER stress. Much more work remains to be done, for example in gaining an understanding of the structural basis for CNPY2-PERK interaction. Nonetheless, our work has uncovered a previously unrecognized molecular mechanism of UPR initiation and raises the possibility of targeting CNPY2 for the treatment of a myriad of UPR-mediated pathological conditions such as NAFLD, obesity, diabetes mellitus, neurodegenerative diseases and cancer.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
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ACknoWLeDgMentS
Authors thank S. Olson who provided the pET28b vector and protocol for purification of His-tagged CNPY2 from the inclusion bodies. We also thank the MUSC protein core for providing the service for the ITC experiments, D. Gewirth, E. Ansa-Addo and S. Parnham for critical reading of the manuscript. The current study was supported by grants from National Institutes of Health (NIH) to Z.L. (R01DK105033, P01CA186866, R01CA213290, R01CA188419 and R01AI070603). Z.L. is supported by the Abney Foundation and the South Carolina SmartState Centers of Economic Excellence. Figure 6 A proposed model for CNPY2 in UPR. Under non-ER stress conditions, grp78 binds to PERK and CNPY2 and thus maintains these proteins in an inactive state. In the presence of ER stress, accumulation of misfolded proteins or alterations in ER homeostasis causes grp78 to dissociate from both PERK and CNPY2 to perform its chaperone function for misfolded proteins. grp78 dissociation along with CNPY2 binding to PERK and perhaps other yet unidentified events collectively initiate the UPR. The activated PERK pathway increases CHOP expression, which in turn transcriptionally upregulates CNPY2 expression.
AUtHoR ContRIBUtIonS
a r t i c l e s ONLINE METHODS
Experimental animals. Cnpy2
Het and KO mice were backcrossed ten generations to a C57B6L/J background before use in the studies. Cnpy2 KO mice and age-matched Het and WT littermates were maintained under specific-pathogenfree conditions and studied according to protocols approved by the Institutional Animal Care and Use Committees of the Medical University of South Carolina and in compliance with guidelines by the Association for Assessment and Accreditation of Laboratory Care International (AAALAC).
Generation of Cnpy2 knockout mice. A fragment of genomic DNA containing murine Cnpy2 exons 2-6 was cloned into a pBluescript-derived plasmid (Stratagene Inc) containing the MC1−HSV−TK cassette. Two fragments flanked on both ends with Frt-PGKneo-Frt-LoxP or LoxP-PGKneo-LoxP were inserted into intron 1 or intron 5, respectively. The PGKneo sequence in intron 5 was removed to generate the first LoxP site. The plasmid was then digested using NotI to linearize the fragment, which was then electroporated into embryonic stem (ES) cells. ES cells were positively selected by G418 and negatively selected by gancyclovir. The drug-resistant target ES cell clones were identified by PCR genotyping and then used to generate the chimera mice by ES-morula aggregation. The chimeric mice were bred with ROSA26-Flpe mice to remove the PGKneo cassette in intron 1 and to generate the second LoxP site. The mice were further crossed with E11a-cre transgenic mice to generate the KO allele (Supplementary Fig. 1a ).
Cnpy2 KO mice were backcrossed onto the C57BL/6J genetic background for more than ten generations for further experiments.
Cell lines. Mouse cell line (RAW 264.7) and human cell lines (HEK293 and Phoenix Eco (PE)) were purchased from American Type Culture Collection (ATCC). We generated MEFs from Cnpy2 WT and KO mice. All culture conditions have been previously described 38 . All cell lines were tested by PCR and found to be mycoplasma negative. Cells were treated with chemicals at the following final concentrations: TG (5 µM) or Tu (1 µg/ml for MEF, 5 µg/ml for other cells) for 16 h, cycloheximide (100 µg/ml for the indicated time, Supplementary  Fig. 5 ). Cell viability was also assessed using trypan blue exclusion. TAC AAT TCA TCC TTG TCG TCA TCG TCT TTG  TAG TCA GAT CTG TGC AGG GCA TGG TC 3′ . The murine Cnpy2 promoter was subcloned into a pGL4 vector (Promega). Primers for the Cnpy2 promoter are 5′ ATC TCG AGG AGT TGA GTT CAA GGC ATC CTG GGC TAC AT 3′ and 5′ ATA AGC TTT TGG AAG ACT TGA GGA CCC AGA C 3′; primers for murine Eif2α are 5′ ATT GCG GCC GCA CCA TGC CGG GGC TAA GTT GTA GAT TTT A 3′ and 5′ GCG CTC GAG TTA ATC TTC AGC TTT GGC TTC CAT TTC 3′. Eif2α was subcloned into a pGEX vector. CNPY2 mutants and eif2α S51A mutants were generated using a site-directed mutagenesis kit (Agilent). His-tagged CNPY2 was subcloned into a pHGK vector. PERK-LD was subcloned into pET28b vector (a gift from S. Olsen, MUSC).
Antibodies
Reverse transcription qPCR.
RNA was extracted from colon tissue using Trizol reagent and quantified with a Nanodrop. mRNA was then reverse transcribed into cDNA using Superscript II Reverse Transcriptase (Invitrogen). cDNA was then diluted so that 10 ng of RNA was used per reaction. RT-qPCR was carried out with SYBR Green Supermix (Bio-Rad) using a Bio-Rad iCycler. Data were exported into Excel for analysis using the ∆C t (the number of PCR cycles to reach the threshold of the product detection) method and normalized to β-actin as an internal control. Plots represent fold change in mRNA. The primers for Edem1  are 5′ CAA TGA AGG AGA AGG AGA CCC 3′ and 5′ GCA TCT TCC ACA  TCC CCT ATC 3′. The primers for Erdj4 are 5′ AAA TAA AAG CCC TGA  TGC TGA AG 3′ and 5′ CCT CTT TGT CCT TTG CCA TTG 3′. The Xbp1s  primers are 5′ ACA CGC TTG GGA ATG GAC AC 3′ and 5′ CCA TGG GAA  GAT GTT CTG GG 3′ .
Retrovirus production and transduction. MigR1-CNPY2 plasmids were transfected into PE packaging cells using Lipofectamine 2000 (ThermoFisher). 6 h after transfection, medium was replaced with prewarmed fresh culture medium. Virus-containing medium was collected at 48 h post transfection. Viral transduction was performed for 8 h at 37 °C in the presence of 8 µg/ml hexadimethrine bromide (Sigma-Aldrich).
Mouse treatment, histopathology and oil red O staining. 8-week-old WT, Cnpy2 Het and KO male mice were injected intraperitoneally with DMSO or Tu (0.4-1 µg/g body weight) for 24 h or fed a HFD (Hanlan, Cat.#88137) for 10 weeks before we harvested the liver and kidneys for histological analysis. Approximately 1-cm segments of tissue were embedded in Optimal Cutting Temperature (OCT) medium (Thermo Scientific) and immediately frozen on dry ice or fixed in 4% formaldehyde in PBS, then dehydrated in 30% sucrose in PBS before embedding in OCT medium. Samples were stored at −80 °C until sectioning. 5-µm sections were cut on a cryostat onto poly-l lysine-coated slides (Sigma-Aldrich). For histological examination, slides were immediately stained with H&E ( Fig. 2c) . For oil red O staining 39 , frozen sections were fixed in formalin, then rinsed with 60% isopropanol. The slides were stained with freshly prepared oil red O solution for 15 min (Fig. 2c) . All pathological analyses were done with the genotypes blinded to the pathologist.
Oligonucleotide pulldown assay and luciferase assay. The sequence of the Cnpy2 promoter oligonucleotide (biotin-labeled and non-biotin-labeled) is CCA CTA CTA ATT GCA TCT GTT TGC AAG TCC TAG CCC ACC TGG ACT (two potential CHOP consensus binding motifs are bolded). The oligonucleotide pulldown assay 29 was achieved with 250 µg of nuclear extracts and 1 µg of biotin-labeled probe. DNA-protein complexes were precipitated using immobilized neutravidin beads (Pierce), then washed and separated by means of SDS-PAGE. Immunoblotting analyses were performed on nuclear extracts and on pulldown complexes (Fig. 5b) . The luciferase assay (Fig. 5d) was performed using the luciferase assay system (Promega) in a luminometer plate reader. The luminescence was measured during a 5 s delay over a 10 s window after the addition of luciferin.
Chromatin immunoprecipitation assay. The assay shown in Figure 5c was performed using a ChIP kit (Active Motif). Briefly, Myc-tagged CHOP-expressing HEK293 cells grown in a 100-mm dish were crosslinked using 1% formaldehyde. After washing three times with PBS, cells were resuspended in lysis buffer. DNA was digested to small fragments (100-500 bp) by enzymatic method. After centrifugation, supernatant was incubated with either anti-Myc antibody or control IgG overnight. Incubation was further carried out with protein G agarose beads for 2 h, and beads were washed with buffers provided in the kit. The immunoprecipitated DNA was eluted from the beads with 1 M NaHCO 3 and 1% sodium sulfate dodecyl solution and reverse crosslinked using 5 M NaCl and RNase A at 65 °C overnight. Samples were then digested with proteinase K, and DNA was purified using the column method. PCR was performed on the purified DNA using CNPY2 and TRB3 promoter-specific primers. The primers for CNPY2 are 5′ CAA ACT ACA GGT CCC AGG ATA G 3′ and 5′ CAC AGG AAA CTA CAT CTC CCA 3′. The primers for TRB3 are 5′ GCA GGG AGA AGG GAG ATA AAC 3′ and 5′ CTA TAT CTG CTG AGT GCC CAT C 3′.
Liver perfusion and isolation of hepatocytes. Liver perfusion and the isolation of hepatocytes were performed according to the procedures described in Severgnini et al. 40 . Briefly, mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight). All buffers were prewarmed to 37 °C. The liver was perfused in situ via the inferior vena cava for 10 min with 0.5 mM EGTA in HBSS buffer, while the portal vein was used as outflow. The flow rate was 6 ml/min and the pressure of perfusion did not exceed a 20-cm water column. The perfusion was continued with the digestion medium (DMEM with low glucose containing 100 U/ml collagenase IV) for 7 min. The liver was isolated from mice and dissociated in cold isolation medium (1:1 ratio of DMEM with high glucose and F-12 containing 10% FBS). The liver cell suspension was filtered through a cell strainer (70 µm), centrifuged and then washed twice with the isolation medium. Cells were seeded in a 10-cm dish at a density of 300,000 /ml for a total of 3 million cells. Cells were incubated at 37 °C for 4 h, after which the culture media was changed to serum-free medium to maintain the morphology of the hepatocytes.
Immunoblotting analysis. Total cell lysates were resolved by SDS-PAGE, and the proteins were transferred onto PVDF membranes. The membranes were blocked with 5% nonfat milk in PBST buffer (8 mM Na 2 HPO 4 , 150 mM NaCl, 2 mM KH 2 PO 4 , 3 mM KCl, 0.05% Tween-20, pH 7.4) and then incubated with primary antibodies, then incubated with HRP-conjugated secondary antibodies. Protein bands were visualized using enhanced chemiluminescent substrate (Pierce).
Sequential immunoprecipitation. Cell lysate extracted from Myc-grp78 and FLAG-CNPY2 cotransfected HEK293 cells was used for sequential immunoprecipitation ( Fig. 3a) . A complex of Myc-grp78 and FLAG-CNPY2 was first coimmunoprecipitated using anti-Myc antibody coupled with protein G beads. This complex was then eluted from the beads using Myc peptides. The complexes from the aliquot elution (1 st IP) were immunoblotted for Myc-grp78 and FLAG-CNPY2. Secondary IP (2 nd IP) was performed using an anti-FLAG antibody to pull down the complex from the elution. Immunoblotting was performed for the indicated proteins.
Protein purification, in vitro binding assay and PERK kinase assay. Nterminally hexahistidine-(His 6×)-tagged/T7-tagged PERK-LD, His 6×-tagged CNPY2 WT and mutant proteins were expressed in BL21 Escherichia coli cells (New England Biolabs). The bacterial cultures were grown at 37 °C to an optical density (OD 600 ) of 0.8 in LB medium supplemented with 50 µg/ml kanamycin and 30 µg/ml chloramphenicol. The cells were further incubated at 37 °C for 6 h for induction of proteins by 0.5 mM IPTG and then harvested by centrifugation and lysed with sonication in buffer (50 mM Tris-HCl, pH 7.4, 350 mM NaCl, 1 mM MgCl2, 0.1 µg/µl DNase I, 2.5 µg/ml Lysozyme, 1 mM β-mercaptoethanol, 10 mM Imidazole) containing protease inhibitor cocktail. The His 6×/T7 tagged PERK-LD lysates were cleared by centrifugation for 30 min at 18,000 r.p.m., and supernatants were transferred to a binding-buffer-equilibrated HisTrap FF column (GE Healthcare Life Sciences). The column was washed with five column volumes of binding buffer (50 mM Tris-HCl, pH 7.4, 350 mM NaCl, and 10 mM Imidazole). The His 6×-tagged PERK-LD proteins were eluted from the column with elution buffer (20 mM Tris, pH 7.4, 500 mM NaCl, 500 mM Imidazole). The His 6×-tagged CNPY2 proteins present in inclusion bodies were denatured in buffer (20 mM Tris, pH 7.4, 500 mM NaCl, 5 mM Imidazole, and 8 M Urea), applied to an equilibrated HisTrap FF column, refolded with the addition of binding buffer (20 mM Tris, pH 7.4, 500 mM NaCl and 5 mM Imidazole) and were eluted from the column with elution buffer (20 mM Tris, pH 7.4, 500 mM NaCl, 500 mM Imidazole). The proteins were concentrated using centrifugal filters (Amicon Ultra, 10 kDa MWCO; Merck Millipore) and stored at −80 °C. N-terminally GST-tagged eif2α WT and mutant (eif2αS51A) proteins were expressed in BL21 E. coli cells. The cells were grown at 37 °C in LB medium containing 100 µg/ml ampicillin. At an OD 600 of 0.8, the cultures were shifted to 30 °C, and expression was induced with 0.5 mM IPTG for an additional 6 h incubation. The cells were harvested and resuspended in buffer (50 mM Tris-HCl, pH 7.4, 350 mM NaCl, 1 mM MgCl 2 , and 0.1% (v/v) Triton X-100) containing protease inhibitor cocktail and DNaseI. The resuspended cells were sonicated for 10 min (Amplitude 60%, pulse on 2 s, pulse off 5 s). The lysates were cleared by centrifugation for 30 min at 18,000 r.p.m. and incubated with 1 ml 50% slurry glutathione Sepharose 4B beads (GE Healthcare) per liter of expression culture for 2 h at 4 °C. The beads were washed twice with 20 ml wash buffer (50 mM Tris-HCl, pH 7.4, 350 mM NaCl, 0.1% (v/v) Triton X-100). Bound proteins were eluted in elution buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM CaCl 2 , 25 mM reduced glutathione), and concentrated protein solutions were applied to FPLC, and GST fusion protein fractions were collected and concentrated for using in Figures 3f, 4c .
The in vitro binding assays shown in Figures 3c,e and 4a were carried out at 37 °C for 1 h in 300 µl of binding buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 2 mM MgCl 2 and 0.1% NP-40) containing 2 µg His/T7 tagged PERK-LD and 3 µg His-tagged CNPY2 or CNPY2 3C-A mutant proteins in the presence or absence of 2 µg of recombinant grp78, followed by 30 min incubation with anti-T7 antibody beads. Immunoprecipitates were then resolved by SDS-PAGE, transferred unto a PVDF membrane and immunoblotted for His tag to detect both PERK-LD and CNPY2. The PERK kinase assay (Figs. 3f and 4e) was previously described 27 . Briefly, the kinase assay was performed at 30 °C for 30 min in 30 µl of kinase buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 1.5 mM DTT, 2 mM MgCl 2 , 0.1 mM ATP) containing 2 µg of purified WT eIF2 or S51A mutant eIF2, or GST alone as a control, 6 µCi of [γ-32 P]ATP (PerkinElmer), immunoprecipitated Myc-tagged PERK from 2 mg of lysates using 3 µg Myc antibody (clone 9E10) coupled with protein G beads. 3 µg of purified CNPY2 was included in one reaction as indicated. Reaction mixtures were spun down and then supernatant was subjected to SDS-PAGE and visualized by autoradiography on an X-ray film. The intensity of bands was measured using the ImageJ software.
Isothermal titration calorimetry (ITC)
. ITC experiments were performed using a Nano isothermal titration calorimeter from TA instruments (Figs. 3d  and 4b and Supplementary Fig. 4 ). Solutions were thoroughly degassed before experiments to avoid air bubbles in the calorimeter. All protein samples were prepared in PBS. For binding of PERK-LD to PBS buffer, CNPY2 or CNPY2 mutant protein, typically 50 µM of CNPY2 or CNPY2 mutant protein was placed in the reaction cell in a 300 µl volume, and 500 µM PERK-LD was placed in the ITC syringe. Aliquots of 1.5 µl were injected into the reaction cell at a 300 s (s) intervals with a stirring speed of 300 rounds per minute and temperature of 20 °C. The titrations were completed after 32 injections. The data were then analyzed using the software Nano Analyzer v2.1.13.
Statistical analysis.
All in vivo experiments were conducted using at least ten randomly selected mice per condition. We justified sample size based on preliminary data from a pilot study that showed expression differences in ER stress genes between Tu-treated WT and CNPY2 KO mice (n = 3 per group). In this experiment, average log-transformed fold-change was −0.71 (corresponding to an average fold change = 0.49), with an IQR of the s.d. of log-transformed mRNA values ranging from 0.24 to 0.55. Assuming a similar effect size, a s.d. as small as 0.24 and as large as 0.55 requires as few as three and as many as ten animals per group to achieve 80% power based on a two-sample t test with twosided α = 0.05. We therefore conservatively conducted most of the subsequent mouse experiments using ten or more animals per group. The actual mouse number for individual experiments is shown in the respective figure legends. For all experiments using primary isolated hepatocytes from randomly selected mice, we used two or three mice per condition for biological replicates and showed only reproducible results. For other in vitro experiments, we performed two or three independent experiments to confirm our findings. Data presented are the mean ± s.d. unless otherwise stated. All statistical significances were determined by the unpaired two-tailed Student's t test using the GraphPad Prism software, version 6.0 (GraphPad Prism Software). P < 0.05 was considered to be statistically significant. All in vivo experiments were conducted using at least 10 randomly selected mice per condition. We justify sample size based on preliminary pilot data (not shown) that shows the difference of ER stress gene expression in tunicamycin-treated WT to CNPY2 KO mice (n = 3 per group). In this experiment, average log-transformed fold-change (FC) was -0.71 (corresponding to an average FC = 0.49), with an IQR of the SD of log-transformed mRNA values ranging from 0.24 to 0.55. Assuming a similar effect size, a SD as small as 0.24 and as large as 0.55 requires as few as 3 and as many as 10 animals per group to achieve 80% power based on a twosample t-test with two-sided α = 0.05. We therefore conservatively conducted all mouse experiments using 10 or more animals per group. The actual mouse number for individual experiment is shown in the figure legend section. For all experiments using primary isolated hepatocytes from randomly selected mice, we use two or three mice per condition for biological replicates and reproducible results. For other in vitro experiments, we performed two or three independent experiment to confirm the consistent results.
Data exclusions
Describe any data exclusions. No data were excluded from the analyses
Replication
Describe whether the experimental findings were reliably reproduced.
For all experiments, we repeated two or three times independently, and were able to find all the results are reproducible.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For animal experiments, it was unbiased to include both male and females mice for each groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Yes. We were blinded to group allocation during data collection and analysis Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Software GraphPad Prism (version 6.01) was used for dot plots and statistic student t test. NanoAnalyze software (v2.1.13) was used for analyzing the isothermal titration calorimetry data. AxioVision (Version 4.8.2.0 ) was used for images of H&E and Oil Red O staining. Software Image Lab (Version 4.0) was used for qRT-PCR gel imaging. Canvas software (Version 11.1) was used for preparing for all figures for this article.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
